ACS, acute  coronary syndrome; DVT/PE, deep  vein thrombosis/pulmonary embolism; 5-FU, 5 fluorouracil; EF, ejection fraction; HF, heart failure; HTN, hypertension; LVSD, left ventricular systolic dysfunction > 2% incidence as clinical HF or symptomatic or asymptomatic fall in EF >10%; mTOR, mammalian Target of Rapamycin; PAD, peripheral arterial disease; PHTN, pulmonary  hypertension; Takutsobo, Takutsobo cardiomyopathy (adapted from Hermann Circ 2016; 133: 1272–89 and Zamorano et al EHJ 2016;37: 2768.